---
title: "Analyst Maintains Buy on Healthcare REIT, Reaffirming $8 Price Target on FFO Growth and Attractive Yield"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284975001.md"
description: "Analyst Michael Diana from Maxim Group has reiterated a Buy rating on Medical Properties Trust, maintaining a price target of $8.00. This decision is based on solid first-quarter results, a clear path to increased cash flow, and growing revenues from repositioned hospitals. Diana notes that normalized FFO covers the dividend comfortably and emphasizes the management's target of $1 billion in annualized cash rent by 2026. He believes the stock is undervalued compared to peers, with an attractive total return including a 7% dividend yield. Colliers Securities also maintains a Buy rating with a $6.50 target."
datetime: "2026-05-02T18:35:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284975001.md)
  - [en](https://longbridge.com/en/news/284975001.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284975001.md)
---

# Analyst Maintains Buy on Healthcare REIT, Reaffirming $8 Price Target on FFO Growth and Attractive Yield

Analyst Michael Diana from Maxim Group reiterated a Buy rating on Medical Properties Trust and keeping the price target at $8.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Michael Diana has given his Buy rating due to a combination of factors, including solid first-quarter results and a visible path to higher cash flow. He highlights that normalized FFO is already comfortably covering the dividend, and that revenues are growing as repositioned, post-bankruptcy hospitals resume and increase rent payments in line with contractual terms.

He also underscores that management reaffirmed its target of at least $1 billion in annualized cash rent by the end of 2026, supported by built-in rent escalators and no need for significant new acquisitions. In his view, the stock’s current valuation multiple is too low relative to healthcare REIT peers, and maintaining an $8 price target reflects both the anticipated FFO ramp and an attractive total return when combined with the approximately 7% dividend yield.

In another report released on April 30, Colliers Securities also maintained a Buy rating on the stock with a $6.50 price target.

### Related Stocks

- [MPW.US](https://longbridge.com/en/quote/MPW.US.md)
- [CIGI.US](https://longbridge.com/en/quote/CIGI.US.md)
- [MPT.US](https://longbridge.com/en/quote/MPT.US.md)

## Related News & Research

- [Do Wall Street Analysts Like Equity Residential Stock?](https://longbridge.com/en/news/286806057.md)
- [Core Scientific Is Firing on All Cylinders as Analysts Approve Its Expansion Plans](https://longbridge.com/en/news/286808678.md)
- [This Analyst Just Sent Mobileye Stock Down. Here's Why.](https://longbridge.com/en/news/286817003.md)
- [American Water Works Stock: Analyst Estimates & Ratings](https://longbridge.com/en/news/286850316.md)
- [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md)